Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Wednesday reported promising preclinical data for its GABAB positive allosteric modulator (PAM) candidate in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF).
Gamma-amino-butyric acid (GABA) is the primary inhibitory neurotransmitter, activating ionotropic (GABAA) and metabotropic (GABAB) receptors. GABAB receptors occur in the peripheral cough neural circuit as well as in the lungs and airways. Targeting these receptors by allosteric modulation can reduce the severity of cough, also known as an antitussive effect.
In preclinical studies on bleomycin (BLM)-exposed animal models, a once-daily administration of the GABAB PAM candidate reduced cough frequency, and increased cough latency. The animal model receiving treatment showed reduced Ashcroft scores, indicating decreased percentage of affected lung tissue. The drug also exhibited a favorable safety profile.
ADXN closed Tuesday at $6.74, up 2.28%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.